{"id":"W4410954797","doi":"10.1016/s0140-6736(25)01040-2","title":"Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"Australia New Zealand Gynaecological Oncology Group","keywords":"Medicine; Internal medicine; Paclitaxel; Oncology; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Ovarian cancer; Bevacizumab; Chemotherapy; Gynecologic oncology; Progressive disease; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001679797,0.001262613,0.002513989,0.0003412405,0.0003312436,0.00111241,0.0008596391,0.00176986,0.006627562],"category_scores_gemma":[0.00182171,0.0005842836,0.002357146,0.0004176114,0.00096167,0.0009270687,0.0004267067,0.003748014,0.001012889],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000860475,"about_ca_system_score_gemma":0.0009151929,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001873103,"about_ca_topic_score_gemma":0.00529969,"domain_scores_codex":[0.9993685,0.0003728292,0.00002716415,0.00009019968,0.00004088597,0.0001004407],"domain_scores_gemma":[0.9991754,0.0002774039,0.0001979003,0.00007279566,0.00003889277,0.0002376464],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9643953,0.003058103,0.0008596526,0.00104856,0.001481899,0.000068578,0.00007161719,0.0003201199,0.002275203,0.0001804979,0.001829073,0.02441151],"study_design_scores_gemma":[0.9719173,0.02477119,0.001494928,0.00004399803,0.0004024268,0.00005052232,0.0000234021,0.0001958903,0.0001432905,0.0001301457,0.0008144256,0.00001259609],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9711965,0.01665801,0.0006474306,0.002138051,0.000907299,0.002455158,0.001557668,0.0002119629,0.004227948],"genre_scores_gemma":[0.9778687,0.007702142,0.001649421,0.002650999,0.0005168905,0.002476602,0.001665739,0.00004709002,0.005422383],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006627562,"threshold_uncertainty_score":0.02217138,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03345300559954077,"score_gpt":0.3406242686957676,"score_spread":0.3071712630962268,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}